Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 9
2020 12
2021 16
2022 17
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

48 results
Results by year
Filters applied: . Clear all
Page 1
Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.
Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L, Rees R, Nardone A, Patterson C, Lennon NJ, Cibulskis C, Leshchiner I, Tayob N, Tolaney SM, Tung N, McDonnell DP, Krop IE, Winer EP, Stewart C, Getz G, Jeselsohn R. Tsuji J, et al. Clin Cancer Res. 2022 Dec 1;28(23):5066-5078. doi: 10.1158/1078-0432.CCR-22-2305. Clin Cancer Res. 2022. PMID: 36215125 Clinical Trial.
Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.
Laws MJ, Ziegler Y, Shahoei SH, Dey P, Kim SH, Yasuda M, Park BH, Nettles KW, Katzenellenbogen JA, Nelson ER, Katzenellenbogen BS. Laws MJ, et al. Breast Cancer Res Treat. 2020 Jun;181(2):297-307. doi: 10.1007/s10549-020-05629-y. Epub 2020 Apr 10. Breast Cancer Res Treat. 2020. PMID: 32277377 Free PMC article.
A comprehensive review on anticancer mechanism of bazedoxifene.
Zafar E, Maqbool MF, Iqbal A, Maryam A, Shakir HA, Irfan M, Khan M, Li Y, Ma T. Zafar E, et al. Biotechnol Appl Biochem. 2022 Apr;69(2):767-782. doi: 10.1002/bab.2150. Epub 2021 Apr 17. Biotechnol Appl Biochem. 2022. PMID: 33759222 Review.
Dual-mechanism estrogen receptor inhibitors.
Min J, Nwachukwu JC, Min CK, Njeri JW, Srinivasan S, Rangarajan ES, Nettles CC, Sanabria Guillen V, Ziegler Y, Yan S, Carlson KE, Hou Y, Kim SH, Novick S, Pascal BD, Houtman R, Griffin PR, Izard T, Katzenellenbogen BS, Katzenellenbogen JA, Nettles KW. Min J, et al. Proc Natl Acad Sci U S A. 2021 Aug 31;118(35):e2101657118. doi: 10.1073/pnas.2101657118. Proc Natl Acad Sci U S A. 2021. PMID: 34452998 Free PMC article.
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer.
Pagliuca M, Donato M, D'Amato AL, Rosanova M, Russo AOM, Scafetta R, De Angelis C, Trivedi MV, André F, Arpino G, Del Mastro L, De Laurentiis M, Puglisi F, Giuliano M. Pagliuca M, et al. Crit Rev Oncol Hematol. 2022 Dec;180:103861. doi: 10.1016/j.critrevonc.2022.103861. Epub 2022 Oct 28. Crit Rev Oncol Hematol. 2022. PMID: 36374739 Free article. Review.
ESR1 mutations: a new biomarker in breast cancer.
Carausu M, Bidard FC, Callens C, Melaabi S, Jeannot E, Pierga JY, Cabel L. Carausu M, et al. Expert Rev Mol Diagn. 2019 Jul;19(7):599-611. doi: 10.1080/14737159.2019.1631799. Epub 2019 Jun 19. Expert Rev Mol Diagn. 2019. PMID: 31188645 Review.
48 results